Framework Agreement for the Purchase of Brineura (cerliponase alfa)

This framework agreement aims to ensure the supply of the pharmaceutical product Brineura (cerliponase alfa) to the hospital pharmacies of Amgros' stakeholders. Additionally, the hospital pharmacy of the Capital Region will undertake procurement for resale to Greenland and the Faroe Islands. This agreement establishes a structured process for acquiring a specific, high-value medication, likely for specialized therapeutic use. The involvement of Amgros and the regional hospital pharmacy indicates a coordinated approach to pharmaceutical procurement within the Danish healthcare system. The framework agreement is designed to provide a reliable and efficient channel for obtaining Brineura, ensuring its availability for patients in the designated regions. The scope covers the supply chain management and distribution of this critical drug, emphasizing consistent access and quality.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.